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Summary
Background The population of patients with estab-
lished coronary artery disease (CAD) is growing be-
cause of an improvement in outcomes and survival
from acute disease episodes. Nevertheless, these pa-
tients remain at high risk of cardiovascular events.
Thus, CAD management is important in prevention
of disease progression. The objective of this analysis
was to describe disease management and clinical out-
come of Austrian outpatients with stable CAD over 5
years by using data from the international CLARIFY
registry.
Methods CLARIFY was an international prospective
observational registry of outpatients with stable CAD,
defined as prior myocardial infarction or revascular-
ization (CABG or PCI), coronary stenosis of more than
50% by coronary angiography or chest pain with my-
ocardial ischemia. We analyzed demographic charac-
teristics, risk factors, treatments and clinical outcomes
of 424 Austrian outpatients with established CAD who
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were enrolled between November 2009 and July 2010
and observed until September 2015.
Results The primary risk factors in Austrian out-
patients with stable CAD were smoking (current
smokers: 13.2%), overweight (77.1%), hypertension
(78.5%), raised low-density lipoprotein (LDL) choles-
terol plasma levels (81.4% ≥ 0.7 g/l or 1.8mmol/l),
elevated heart rate (≥70 bpm: 60.9% in patients
with anginal symptoms) and poor physical activity
(none or light activity: 63.4%). Patients received
lipid-lowering drugs (predominantly statins), aspirin,
beta-blockers and angiotensin-converting enzyme
(ACE) inhibitors according to current recommenda-
tions. After 5 years a systolic blood pressure (SBP) <
140mmHg and diastolic blood pressure (DBP) <
90mmHg was reached in 58.5% of patients. Of the
patients 70.4% had LDL cholesterol plasma levels
below 1.0 g/l (2.6mmol/l), 42.1% of smokers had
stopped smoking, 42.9% of patients with anginal
symptoms had a heart rate ≤60 bpm and 26.0% of di-
abetic patients had brought their HbA1c levels below
6.5%. Cardiovascular death, myocardial infarction
or stroke occurred in 30 patients (7.1%), all-cause
death in 25 cases (5.9%) and cardiovascular death in
15 cases (3.5%). Myocardial infarction was reported
in 14 patients (fatal and non-fatal: 3.3%) and stroke
in 8 patients (fatal and non-fatal: 1.9%), 39 patients
(9.2%) underwent myocardial revascularization and
124 patients (29.2%) experienced cardiovascular hos-
pitalization.
Conclusion Characteristics of Austrian outpatients
with stable CAD corresponded to those of patients
with CAD in other developed countries. Medical
treatments following the recommendations of the
European guidelines were prescribed in the major-
ity of patients; however, recommended goals of life
style interventions including a heart rate less than
60 bpm and general risk factor management were not
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achieved by a high proportion of patients. Heart rate
control and life style changes remain unmet needs of
cardiovascular care in Austria.
Keywords Coronary artery disease · CLARIFY · Treat-
ment · Clinical outcome · Austria
Introduction
Approximately 17.5 million people die each year from
cardiovascular disease. An estimated 30% of all deaths
worldwide are due to heart attacks and strokes. Coro-
nary artery disease (CAD) accounts for the greatest
proportion of cardiovascular diseases. Overall, CAD
is the leading cause of death worldwide and is pre-
dicted to remain so for the next 20 years [1–3]. In Eu-
rope between 14% and 20% of women and 16–25% of
men die from CAD [4]. Furthermore, CAD is a leading
cause of morbidity and poor quality of life. Thus, CAD
is a major public health problem which exerts heavy
economic costs. Overall, CAD is estimated to have
cost the European Union 45 billion in 2003 and this
estimate even might be an underestimate [5]. Nev-
ertheless, improved management of the disease con-
sisting of life style interventions, revascularization or
optimal drug therapy have resulted in a decrease in
CAD mortality since 1995 by 34% [6, 7]; however, most
data regarding CAD are from patients with acute coro-
nary symptoms or in the case of patients with stable
CAD come from randomized trials of drugs used in
the prevention of cardiovascular events (e. g. EUROPA
[8]). In order to generalize the findings from these
trials, real-life aspects regarding demography and dis-
ease management of outpatients with stable CAD are
needed. Because of the improvement in outcomes
and survival from episodes of acute disease, the pop-
ulation of patients with established CAD is growing.
All these patients remain at high risk of cardiovascu-
lar events and therefore disease management is im-
portant in prevention of disease progression [9, 10].
The prospeCtive observational LongitudinAl Reg-
Istry oF patients with stable coronary arterY disease
(CLARIFY) registry was initiated to improve knowl-
edge regarding patients with stable CAD. The registry
was designed to collect data on the current status
of outpatients with stable CAD, including demogra-
phy, clinical profiles, therapeutic strategies and clin-
ical outcomes. In this context, the registry includes
symptomatic and asymptomatic patients. The main
objectives were to define contemporary patients with
stable CAD, to identify discrepancies between evi-
dence-based recommendations and practice, and to
investigate long-term prognostic determinants [10,
11].
This analysis describes disease management and
clinical outcomes of Austrian outpatients with sta-
ble CAD over 5 years of CLARIFY. Success in disease
management and treatment were evaluated by analy-
sis of patients who achieved the following treatment
targets: normalized blood pressure, lowered low-den-
sity lipoprotein (LDL) cholesterol levels, heart rate
≤60 bpm in patients with angina, smoking cessation,
and lowered glycated hemoglobin (HbA1c) levels in
diabetic patients. In addition, the analysis included
a comparison of heart rate and usage of heart rate-
modulating medications of Austrian CAD patients
with European CAD patients.
Materials and methods
Study design and patients
CLARIFY was an international, prospective, observa-
tional, longitudinal registry in stable CAD outpatients
with 5 years of follow-up. The study rationale, design
andmethods were described previously [10, 12]. Over-
all, patients were enrolled in 45 countries worldwide.
They were treated according to usual clinical practice
at each institution, with no specific tests or therapies
defined in the study protocol.
Patients were enrolledwhen theymet at least one of
the following inclusion criteria: documented myocar-
dial infarction (more than 3 months ago), coronary
stenosis of more than 50% proven by coronary angiog-
raphy, chest pain with myocardial ischemia proven
by stress electrocardiogram, stress echocardiography
or myocardial imaging, and coronary artery bypass
grafting (CABG) surgery or percutaneous coronary in-
tervention (PCI) more than 3 months ago. Patients
were excluded in cases of hospitalization for cardio-
vascular disease within the past 3 months (includ-
ing revascularization) and planned revascularization
as well as patients with conditions expected to hamper
participation or the 5-year follow-up, such as limited
cooperation, limited legal capacity, serious non-car-
diovascular disease or conditions interfering with life
expectancy (e. g. cancer, drug abuse) or severe cardio-
vascular disease (e. g. advanced heart failure, severe
valve disease, history of valve repair and/or valve re-
placement).
To ensure that the study population was repre-
sentative of a real-life population of stable CAD out-
patients in each country, recruitment was based on
a predefined selection of physician types (cardiolo-
gists, internists, primary care physicians) and aimed
for consecutive enrolment of eligible patients. Each
physician recruited a maximum of 15 outpatients
with stable CAD as defined by the inclusion crite-
ria, the general target enrolment for any participating
country was 25 patients per million inhabitants (range
12.5–50). The first patient was included on 26 Novem-
ber 2009 and recruitment was completed on 30 June
2010. The registry ended in September 2015. A total
of 424 Austrian patients were included in the registry,
28.1% of patients were lost to follow-up after 5 years.
The study was registered in the ISRCTN registry of
clinical trials (ISRCTN43070564).
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Data collection and data management
Investigators completed electronic case report forms
(eCRFs) at baseline and at patient visits 1 year,
2 years, 3 years, 4 years and 5 years after enrolment
(±3 months). Data collected at baseline included
demographics, risk factors and life style, medical his-
tory and current symptoms, physical examination
including heart rate determined by pulse palpation
and the results of the most recent electrocardio-
gram (ECG) performed within the past 6 months,
laboratory values (if available: fasting blood glucose,
HbA1c, cholesterol, including total cholesterol, high-
density lipoprotein cholesterol (HDL), LDL, triglyc-
erides, plasma creatinine, and hemoglobin), and cur-
rent chronic medical treatments taken by the patient
for more than 7 days prior to inclusion in the reg-
istry. During annual follow-up visits the following
information was collected: employment status, risk
factors and life style, current symptoms, physical ex-
amination including heart rate, laboratory values (if
available), current treatments and clinical events oc-
curring since the last visit, e.g. all-cause death, fatal
or non-fatal myocardial infarction (MI), fatal or non-
fatal stroke, cardiovascular death, unstable angina,
major bleeding, coronary angiography, and revascu-
larization percutaneous coronary intervention (PCI)
and CABG, transient ischemic attack (TIA), hospital-
ization for congestive heart failure (CHF) and car-
diovascular hospitalization. Completed eCRFs were
electronically sent to the data management center in
Glasgow (Robertson Centre for Biostatistics, Univer-
sity of Glasgow, UK) where checks for completeness,
internal consistency and accuracy were run.
The study was performed in accordance with the
principle of the Declaration of Helsinki and was ap-
proved by the National Research Ethics Service, Isle
of Wright, Portsmouth and Southeast Hampshire Re-
search Ethics Committee, UK. Approval was also ob-
tained in Austria, in accordance with local regulations
before recruitment of the first participant. All patients
signed a written informed consent to participate, in
accordance with national and local guidelines.
Statistical analysis
All data were collected and analyzed at an indepen-
dent academic statistic center at the Robertson Centre
for Biostatistics, University of Glasgow, UK which was
responsible for data management, statistical analy-
ses and storage of the data according to regulations.
The main analyses were designed to describe patient
characteristics at baseline and to estimate the annual
cardiovascular event rates, and the outcome event
rates by region and country. Baseline variables as well
as parameters collected in the annual follow-up vis-
its were summarized as means, standard deviations
(SD), medians, interquartile ranges (IQR), and ranges
for continuous data and as counts and percentages
for categorical data. Summaries were provided for
CLARIFY Austria and for CLARIFY Austria and sub-
jects with angina. Statistical analysis was performed
using the statistical package R, version 3.1.2 [13].
Height and weight were used to calculate body mass
index (BMI) in kg/m2. Outcome was defined as oc-
currence of death and/or any cardiovascular events,
such as MI or stroke during the observation period.
Treatment targets were defined as normalized blood
pressure (<140/90mmHg), lowered LDL cholesterol
plasma levels (<0.7 g/l or <1.0 g/l), lowered HbA1c
levels in diabetic patients (<6.5% or <7.0%), heart
rate ≤60 bpm in patients with anginal symptoms and
smoking cessation.
Results
In Austria, 424 patients with stable CAD were included
in the CLARIFY registry of which 75.0% were male and
the mean age was 65.2 ± 10.1 years. The most frequent
concomitant diseases were dyslipidemia and treated
hypertension, 53.3% had a medical history of MI and
77.6% had had a PCI in the past and 33.5% of pa-
tients had a family history of premature CAD. Symp-
toms of chronic heart failure were present in 12.3%.
At baseline, mean BMI was 27.7 ± 3.9 kg/m2 and mean
blood pressure was within the normal range. Resting
heart rate measured by pulse palpation was 68.3 ±
10.3 bpm and by ECG 67.2 ± 10.8 bpm, 57.1% of pa-
tients were former or current smokers. The most pre-
dominant CAD risk factors were overweight and ele-
vated LDL cholesterol plasma levels. Most patients re-
ported regular light physical activities (52.8%), 46 pa-
tients (10.8%) with stable CAD were affected by angi-
nal symptoms and 65.2% of these patients were male
but the proportion of patients with anginal symptoms
was higher in women than in men (15.1% in women
vs. 9.4% in men). Angina was classified as grade II ac-
cording to the Canadian Cardiovascular Society (CCS)
classification in most cases. Mean age of patients
with anginal symptoms was 68.6 ± 9.2 years and dys-
lipidemia was the most frequently documented con-
comitant disease. Compared with the complete Aus-
trian patient population, previous PCI was less com-
mon in patients with angina but symptoms of chronic
heart failure were more common after previous PCI.
In addition, patients with angina showed a slightly
higher mean BMI and higher mean heart rate. Over-
all, in 60.9% of patients with angina heart rate was
≥70 bpm. The most common risk factors were ele-
vated LDL cholesterol plasma levels and overweight.
In addition, 32.6% of patients with angina were former
smokers and 28.3% current smokers (Table 1).
At baseline, the majority of patients were treated
with lipid-lowering drugs (LLD) (94.6%, predomi-
nantly statins: 89.3%), aspirin (86.6%) and beta-block-
ers (78.8%). Angiotensin-converting enzyme (ACE)
inhibitors were used in 45.0% and 33.0% received di-
uretics. Trimetazidine and ranolazine were not used.
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Table 1 Baseline charac-
teristicsAustrian
Parameter Patients with stable CAD
(N = 424)
Patients with stable CAD and
angina (N = 46)
Age (mean years ± SD) 65.2 (10.1) 68.6 (9.2)
Gender (N [%])
Male 318 (75.0) 30 (65.2)
Female 106 (25.0) 16 (34.8)
Employment
Employed full-time 94 (22.2) 3 (6.5)
Employed half-time 11 (2.6) 2 (4.3)
Unable to work 3 (0.7) 0 (0.0)
Unemployed 4 (0.9) 2 (4.3)
Retired 310 (73.1) 38 (82.6)
Other 2 (0.5) 1 (2.2)
Education
Primary school (or less) 214 (50.5) 29 (63.0)
Secondary school 169 (39.9) 16 (34.8)
College/University 41 (9.7) 1 (2.2)
Concomitant diseases and lifestyle (N [%])
Family history of premature CADa 142 (33.5) 14 (30.4)
Treated hypertension 333 (78.5) 40 (87.0)
Diabetes 121 (28.5) 19 (41.3)
Dyslipidemiab 375 (88.4) 42 (91.3)
PAD 64 (15.1) 11 (23.9)
Alcohol intake, glasses per week
0 99 (23.3) 14 (30.4)
>0 to <20 316 (74.5) 31 (67.4)
>20 9 (2.1) 1 (2.2)
Stimulant drinks
Coffee 311 (73.3) 37 (80.4)
Tea 29 (6.8) 6 (13.0)
Neither 84 (19.8) 3 (6.5)
Physical activity
None 45 (10.6) 6 (13.0)
Lightc 224 (52.8) 32 (69.6)
1–2 times per weekd 81 (19.1) 7 (15.2)
≥3 times per weekd 74 (17.5) 1 (2.2)
Medical history N (%)
Myocardial infarction 226 (53.3) 21 (45.7)
PCI 329 (77.6) 31 (67.4)
CABG 99 (23.3) 12 (26.1)
Abdominal aortic aneurysm 10 (2.4) 1 (2.2)
Coronary stenosise 54 (12.7) 14 (30.4)
ICD 6 (1.4) 0 (0.0)
Pacemaker 7 (1.7) 1 (2.2)
Stroke 17 (4.0) 5 (10.9)
TIA 13 (3.1) 3 (6.5)
Hospitalization for CHF 13 (3.1) 2 (4.3)
Atrial fibrillation/flutter 39 (9.2) 4 (8.7)
Asthma/COPD 52 (12.3) 12 (26.1)
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Table 1 (Continued) Parameter Patients with stable CAD
(N = 424)
Patients with stable CAD and
angina (N = 46)
Current symptoms (N [%])
Angina 46 (10.8) 46 (100.0)
CCS class (if angina)
I 14 (30.4) 14 (30.4)
II 25 (54.3) 25 (54.3)
III 7 (15.2) 7 (15.2)
CHF symptoms 52 (12.3) 15 (32.6)
NYHA class (if CHF)
II 45 (86.5) 13 (86.7)
III 7 (13.5) 2 (13.3)
Measurements
Weight [kg] 81.4 81.0
Height [cm] 171.5 170.0
BMI, mean (SD) [kg/m2] 27.7 (3.9) 28.0 (4.9)
Heart rate (by pulse palpation), mean (SD) [bpm] 68.3 (10.3) 73.8 (13.8)
Heart rate (by pulse ECG), mean (SD) [bpm] 67.2 (10.8) 72.0 (14.3)
Heart rate ≥70 bpm (in angina patients) – 28 (60.9)
SBP, mean (SD), [mm Hg] 133.8 (16.6) 135.3 (18.2)
DBP mean (SD), [mm Hg] 80.0 (9.1) 80.4 (10.7)
Waist circumference, mean (SD), [cm] 99.2 (11.2) 101.5 (13.9)
Risk factors (N (%))
Overweight f 327/424 (77.1) 34/46 (73.9)
Obesityg 99/424 (23.3) 15/46 (32.6)
Smoking status, N 424 46
Current 56 (13.2) 13 (28.3)
Former 186 (43.9) 15 (32.6)
Never 182 (42.9) 18 (39.1)
Raised blood pressureh 175/424 (41.3) 23/46 (50.0)
Raised LDL cholesterol 1i 126/370 (34.1) 12/39 (30.8)
Raised LDL cholesterol 2j 301/370 (81.4) 31/39 (79.5)
Lowered HDL cholesterolk 66/379 (17.4) 12/42 (28.6)
Raised HbA1cl 46/121 (38.0) 5/19 (26.3)
HR on palpation ≥70 bpmm – 28/46 (60.9)
BMI body mass index, bpm beats per minute, CABG coronary artery bypass graft, CAD coronary artery disease,
CCS Canadian Cardiovascular Society, CHF chronic heart failure, COPD chronic obstructive pulmonary disease,
DBP diastolic blood pressure, ECG electrocardiogram, HbA1c glycated hemoglobin, HDL high-density lipoprotein,
HR heart rate, ICD internal cardiac defibrillator, LDL low-density lipoprotein, N number of patients, NYHA New York
Heart Association, PAD peripheral artery disease, PCI percutaneous coronary intervention, SBP systolic blood pressure,
SD standard deviation, TIA transient ischaemic attack
aMyocardial infarction, sudden death, stable angina at age <55 years (men) or <65 year (women) in a first-degree
relative
bDefined as history of documented total cholesterol >2 g/l or >5.18 mmol/l or high-density lipoprotein cholesterol
<0.4 g/l or <1mmol/l
cLight physical activity most weeks
dAt least 20 min vigorous physical activity
eCoronary territories with stenosis >50% at coronary angiography or required revascularization in medical history
fDefined as BMI ≥25–29.99 kg/m2
gDefined as BMI ≥30 kg/m2
hDefined as systolic blood pressure ≥140mmHg and diastolic blood pressure ≥90mmHg
iDefined as LDL cholesterol plasma level ≥1 g/l or 2.6mmol/l
jDefined as LDL cholesterol plasma level ≥0.7 g/l or 1.8mmol/l
kDefined as HDL cholesterol plasma level ≤40mg/dl or 1.0 mmol/l
lin diabetic patients, defined as HbA1c level ≥7.0%
monly in angina patients
nmean values as well as percentages are of the data available
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The most frequently received other medications were
proton pump inhibitors (PPI) and antidiabetic agents.
During the 5 years of CLARIFY, there were only few
alterations to these treatments and LLD (predomi-
nantly statins), aspirin and beta-blockers were the
primary medications on follow-up. The usage of
LLD was relatively stable, whereas the proportion of
patients who received aspirin, beta-blockers or ACE
inhibitors decreased over time. In contrast, the use of
diuretics and angiotensin II (AT II) receptor inhibitors
increased over time. With respect to other medica-
tions the proportion of patients who received non-
steroidal anti-inflammatory drugs (NSAIDs) slightly
decreased. All other treatments remained the same
(Table 2).
Table 2 TreatmentofAustrianpatientswithstableCADandAustrianpatientswith stableCADandanginaduringobservation (N
[%])a
Parameter Baseline 1st year 2nd year 3rd year 4th year 5th year
Patients with stable CAD (N [%])
N 424 411 351 337 323 305
Aspirin 367 (86.6) 333 (82.2) 268 (79.1) 248 (75.8) 231 (74.5) 213 (73.2)
Thienopyridines 38 (9.0) 42 (10.4) 35 (10.3) 34 (10.4) 34 (11.0) 30 (10.3)
Other antiplatelet agent 44 (10.4) 39 (9.6) 31 (9.1) 34 (10.4) 32 (10.3) 33 (11.3)
Oral anticoagulant 46 (10.8) 44 (10.9) 45 (13.3) 45 (13.8) 48 (15.5) 46 (15.8)
Beta-blocker 334 (78.8) 304 (75.1) 249 (73.5) 235 (71.9) 223 (71.9) 202 (69.4)
Ivabradine 25 (5.9) 26 (6.4) 18 (5.3) 17 (5.2) 15 (4.8) 16 (5.5)
Calcium antagonists 76 (17.9) 74 (18.3) 60 (17.7) 63 (19.3) 55 (17.7) 52 (17.9)
Verapamil or dilitiazem 15 (3.5) 15 (3.7) 11 (3.2) 10 (3.1) 8 (2.6) 6 (2.1)
ACE inhibitors 191 (45.0) 175 (43.2) 145 (42.8) 134 (41.0) 122 (39.4) 117 (40.2)
AT II receptor-blocker 120 (28.4) 120 (29.6) 105 (31.0) 100 (30.6) 97 (31.3) 89 (30.6)
LLD 401 (94.6) 378 (93.3) 316 (93.2) 300 (91.7) 284 (91.6) 267 (91.8)
Statins (if LLD) 358 (89.3) 321 (84.9) 261 (82.6) 246 (82.0) 230 (81.0) 213 (79.8)
Other antianginal agent 50 (11.8) 50 (12.3) 38 (11.2) 40 (12.2) 37 (11.9) 32 (11.0)
Trimetazine 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ranolazine 0 (0.0) 1 (0.2) 2 (0.6) 4 (1.2) 4 (1.3) 3 (1.0)
Diuretics 140 (33.0) 135 (33.3) 119 (35.1) 111 (33.9) 111 (35.8) 105 (36.1)
Other hypertensive agent 47 (11.1) 50 (12.3) 39 (11.5) 36 (11.0) 34 (11.0) 29 (10.0)
Digoxin and derivates 10 (2.4) 9 (2.2) 8 (2.4) 7 (2.1) 7 (2.3) 9 (3.1)
Amiodarone/dronedarone 17 (4.0) 16 (4.0) 13 (3.8) 13 (4.0) 12 (3.9) 11 (3.8)
Other antiarrhythmics 8 (1.9) 8 (2.0) 10 (2.9) 8 (2.4) 8 (2.6) 7 (2.4)
Other medication
NSAIDs 44 (10.4) 44 (10.9) 35 (10.3) 28 (8.6) 27 (8.7) 22 (7.6)
Antidiabetic agents 82 (19.3) 76 (18.8) 56 (16.5) 56 (17.2) 54 (17.4) 53 (18.4)
PPI 151 (35.6) 144 (35.6) 114 (33.5) 106 (32.6) 109 (35.2) 99 (34.4)
THoR 48 (11.3) 47 (11.6) 40 (11.8) 39 (12.0) 36 (11.6) 31 (10.8)
HoR 1 (0.2) 1 (0.2) 1 (0.3) 1 (0.3) 1 (0.3) 1 (0.3)
Drug for ED 8 (1.9) 8 (2.0) 5 (1.5) 5 (1.5) 4 (1.3) 3 (1.0)
Patients with stable CAD and angina
N 46 35 25 14 16 7
Aspirin 43 (93.5) 28 (80.0) 20 (80.0) 13 (92.9) 13 (81.2) 5 (71.4)
Thienopyridines 4 (8.7) 6 (17.1) 7 (28.0) 1 (7.1) 2 (12.5) 0 (0.0)
Other antiplatelet agent 2 (4.3) 2 (5.7) 1 (4.0) 1 (7.1) 1 (6.2) 1 (14.3)
Oral anticoagulant 5 (10.9) 5 (14.3) 4 (16.0) 3 (21.4) 3 (18.8) 0 (0.0)
Beta-blocker 35 (76.1) 18 (51.4) 20 (80.0) 11 (78.6) 13 (81.2) 5 (71.4)
The primary treatment of patients with angina at
baseline did not differ from the treatments of the
whole Austrian patient population. Most of them
received LLD (91.3%, statins: 85.7%), aspirin (93.5%),
beta-blockers (76.1%) and other antianginal agents
(32.6%); however, ivabradine, calcium antagonists,
verapamil or dilitiazem, other antihypertensive agents
as well as digoxin and derivates were more frequently
used in patients with angina. The ACE inhibitors and
diuretics were less frequently used. In addition, 45.7%
of patients with anginal symptoms were treated with
PPI, 32.6% with antidiabetic agents and 23.9% with
NSAIDs. Throughout the follow-up period, treatments
with aspirin, calcium antagonists and ivabradine saw
a declining trend, whilst use of diuretics saw an in-
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Table 2 (Continued)
Parameter Baseline 1st year 2nd year 3rd year 4th year 5th year
Ivabradine 11 (23.9) 8 (22.9) 2 (8.0) 1 (7.1) 0 (0.0) 0 (0.0)
Calcium antagonists 14 (30.4) 11 (31.4) 4 (16.0) 4 (28.6) 3 (18.8) 2 (28.6)
Verapamil or dilitiazem 4 (8.7) 5 (14.3) 2 (8.0) 1 (7.1) 1 (6.2) 0 (0.0)
ACE inhibitors 18 (39.1) 14 (40.0) 11 (44.0) 6 (42.9) 5 (31.2) 3 (42.9)
AT II receptor-blocker 15 (32.6) 14 (40.0) 7 (28.0) 7 (50.0) 7 (43.8) 1 (14.3)
LLD 42 (91.3) 32 (91.4) 23 (92.0) 14 (100.0) 15 (93.8) 7 (100.0)
Statins (if LLD) 36 (85.7) 25 (78.1) 17 (73.9) 7 (50.0) 10 (66.7) 4 (57.1)
Other antianginal agent 15 (32.6) 12 (34.3) 9 (36.0) 8 (57.1) 7 (43.8) 3 (42.9)
Trimetazine 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ranolazine 0 (0.0) 1 (2.9) 2 (8.0) 3 (21.4) 1 (6.2) 1 (14.3)
Diuretics 14 (30.4) 16 (45.7) 12 (48.0) 9 (64.3) 9 (56.2) 3 (42.9)
Other hypertensive agent 7 (15.2) 8 (22.9) 4 (16.0) 4 (28.6) 3 (18.8) 1 (14.3)
Digoxin and derivates 3 (6.5) 2 (5.7) 2 (8.0) 1 (7.1) 1 (6.2) 0 (0.0)
Amiodarone/dronedarone 2 (4.3) 3 (8.6) 1 (4.0) 0 (0.0) 0 (0.0) 1 (14.3)
Other antiarrhythmics 0 (0.0) 0 (0.0) 2 (8.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other medication
NSAIDs 11 (23.9) 6 (17.1) 3 (12.0) 2 (14.3) 1 (6.2) 1 (20.0)
Antidiabetic agents 15 (32.6) 5 (14.3) 3 (12.0) 1 (7.1) 2 (12.5) 0 (0.0)
PPI 21 (45.7) 15 (42.9) 9 (36.0) 6 (42.9) 7 (43.8) 3 (60.0)
THoR 6 (13.0) 5 (14.3) 4 (16.0) 2 (14.3) 1 (6.2) 0 (0.0)
HoR 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Drug for ED 1 (2.2) 1 (2.9) 1 (4.0) 0 (0.0) 0 (0.0) 0 (0.0)
ACE angiotensin-converting enzyme, AT angiotensin, CAD coronary artery disease, ED erectile dysfunction, HoR hormone replacement therapy, LLD lipid-lowering
drug, N number of patients, NSAIDs non-steroidal anti-inflammatory drugs, PPI proton pump inhibitor, THoR thyroid hormone replacement therapy
apercentages are of the data available
creasing trend. The proportion of patients who were
treated with LLD was very stable, but treatment with
statins decreased. In addition, there was also a de-
cline in the use of antidiabetic agents as well as
thyroid hormone replacement therapies (Table 2).
Analysis of patient status over 5 years of CLARIFY
follow-up showed no changes in mean body weight
and mean BMI as well as no changes in systolic and
diastolic blood pressure as well as heart rate. The
prevalence of overweight, obesity and elevated LDL
cholesterol plasma levels declined, but there was an
increase in the proportion of patients with low HDL
cholesterol plasma levels. Overall the proportion of
smoking patients decreased, and only 1.9% of patients
who did not smoke at baseline were current smokers
in the 5th year (Table 3).
The proportion of patients with angina decreased
from 8.6% after the 1st year to 2.3% in the 5-year fol-
low-up. In addition, these patients showed a decrease
in mean body weight and mean BMI. Furthermore,
there was a decline inmean heart rate, and a heart rate
≥70 bpm was less common. In contrast, blood pres-
sure increased and elevated blood pressure was more
common in year 5 of CLARIFY compared to the year 1
assessment. The LDL cholesterol plasma levels did
not change and the proportion of patients with lower
HDL cholesterol plasma levels was growing, similar to
the total Austrian patient population (Table 3).
At the end of the observation period, blood pres-
sure was normalized in 58.5% of outpatients with sta-
ble CAD and treated hypertension, which was defined
as SBP <140mmHg and DBP <90mmHg. Of the pa-
tients 70.4% had LDL cholesterol plasma levels be-
low 1.0 g/l (2.6mmol/l) and 24.5% had LDL choles-
terol plasma levels <0.7 g/l (1.8mmol/l), 42.1% of cur-
rent smokers at baseline had stopped smoking during
CLARIFY, 42.9% of patients with anginal symptoms
achieved a heart rate ≤60 bpm and 26.0% of diabetic
patients could reduce their HbA1c levels below 6.5%
(Table 4).
The primary outcome, defined as the composite of
cardiovascular death, MI or stroke over 5 years oc-
curred in 7.1% of Austrian patients and 8.7% of pa-
tients from the rest of the CLARIFY population. Car-
diovascular death was observed in 3.5% of Austrian
patients and 5.0% of patients in the rest of CLARIFY,
all-cause death in 5.9% and 7.9% of each population,
respectively and hospitalization for heart failure in
3.5% and 5.1%. The frequency of MI (fatal or non-
fatal) and stroke (fatal or non fatal) was very similar
between the populations (MI was observed in 3.3%
and 3.4% of each population and stroke was observed
in 1.9% and 2.1% of each population) (Table 5).
European outpatients with CAD had a slightly lower
heart rate than Austrian patients. The same could be
found in patients with anginal symptoms at baseline
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Table 3 Patient characteristicsofAustrianpatientswith stableCADandAustrianpatientswith stableCADandanginaduring
observationi
Parameter 1st year 2nd year 3rd year 4th year 5th year
Patients with stable CAD (N [%])
N 411 351 337 323 305
Weight [kg] 81.6 (13.8) 81.9 (13.5) 82.1 (14.7) 81.9 (13.5) 81.4 (14.0)
BMI, mean (SD) [kg/m2] 27.7 (4.0) 27.9 (4.0) 27.9 (4.3) 27.7 (3.9) 27.6 (3.9)
HR (palpation), mean (SD) [bpm] 66.7 (9.6) 66.2 (9.9) 66.4 (11.3) 66.4 (10.3) 67.3 (11.3)
HR (ECG), mean (SD) [bpm] 66.0 (10.0) 65.8 (9.8) 66.1 (11.5) 66.5 (11.3) 67.0 (11.0)
SBP, mean (SD), [mm Hg] 133.4 (17.4) 132.9 (18.8) 133.3 (17.1) 134.3 (17.9) 133.7 (16.8)
DBP mean (SD), [mm Hg] 79.3 (9.3) 78.5 (9.5) 78.8 (9.4) 78.9 (9.7) 78.4 (9.4)
Waist circumference, mean (SD), [cm] 99.3 (12.0) 98.6 (11.5) 99.7 (13.1) 99.4 (11.2) 100.1 (13.6)
Overweight (%)a 305 (76.2) 270 (78.3) 253 (76.0) 232 (75.6) 224 (75.7)
Obesity (%)b 98 (24.5) 85 (24.6) 78 (23.4) 74 (24.1) 67 (22.6)
Smoking status (%)
Current 45 (11.0) 35 (10.1) 33 (9.9) 29 (9.1) 27 (9.1)
Former 189 (46.3) 157 (45.2) 153 (45.7) 135 (42.5) 114 (38.3)
Never 174 (42.6) 155 (44.7) 149 (44.5) 154 (48.4) 157 (52.7)
Raised blood pressure (%)c 163 (40.8) 125 (36.2) 120 (36.0) 129 (42.0) 117 (39.5)
Raised LDL cholesterol 1 (%)d 120 (36.4) 96 (34.9) 86 (34.1) 72 (30.0) 69 (30.5)
Raised LDL cholesterol 2 (%)e 274 (83.0) 225 (81.8) 206 (81.7) 193 (80.4) 173 (76.5)
Lowered HDL cholesterol (%)f 58 (16.6) 48 (16.8) 52 (19.3) 53 (21.2) 55 (23.3)
Raised HbA1c (%)g 33 (28.0) 22 (23.2) 32 (35.6) 30 (36.1) 24 (31.2)
Smoking initiation (%)h 6 (1.7) 4 (1.3) 5 (1.7) 4 (1.4) 5 (1.9)
Patients with stable CAD and angina
N (%) 35 (8.6) 25 (7.2) 14 (4.2) 16 (5.0) 7 (2.3)
Weight [kg] 79.5 (15.3) 81.9 (13.0) 79.7 (12.9) 76.9 (12.1) 71.7 (15.3)
BMI, mean (SD) [kg/m2] 26.9 (4.1) 27.1 (3.5) 27.2 (3.0) 27.6 (4.3) 24.0 (4.4)
HR (palpation), mean (SD) [bpm] 69.5 (11.4) 65.3 (12.0) 71.1 (16.9) 63.8 (9.0) 62.3 (4.8)
HR (ECG), mean (SD) [bpm] 68.5 (10.2) 65.1 (13.5) 68.4 (16.3) 63.9 (9.3) 63.3 (6.4)
HR ≥ 70 bpm (palpation) 17 (48.6) 5 (20.0) 6 (42.9) 3 (18.8) 1 (14.3)
SBP, mean (SD), [mm Hg] 129.8 (16.2) 131.8 (22.3) 140.0 (20.2) 136.8 (20.7) 138.0 (19.1)
DBP mean (SD), [mm Hg] 77.2 (10.3) 78.7 (8.4) 79.7 (13.5) 72.8 (11.3) 81.0 (14.8)
Waist circumference, mean (SD), [cm] 97.9 (13.5) 101.0 (11.7) 99.6 (11.6) 99.7 (15.1) 94.7 (12.9)
Overweight (%)a 24 (68.6) 19 (79.2) 11 (78.6) 10 (66.7) 3 (50.0)
Obesity (%)b 9 (25.7) 4 (16.7) 2 (14.3) 5 (33.3) 1 (16.7)
but during the years of CLARIFY, the heart rate of Aus-
trian patients with angina showed a stronger decline
than the heart rate of patients with angina in the rest
of Europe. In addition, the proportion of patients with
heart rates above 70 bpm was lower among Austrian
patients with angina at the end of documentation and
relatively more Austrian patients with angina achieved
a heart rate below 60 bpm. With respect to therapeu-
tic heart rate-modulators, it could be seen that Aus-
trian patients as well as patients from other European
countries were primarily treated with beta-blockers.
Differences could be found in the usage of ivabra-
dine. Patients from other European countries were
more frequently treated with ivabradine than Austrian
patients, especially patients with angina. Verapamil or
dilitiazem as well as digoxin and derivates played only
a minor role in both (Table 6).
Discussion
This analysis describes disease management and clin-
ical outcome of Austrian outpatients with stable CAD
as well as risk factors and life style management over 5
years of the CLARIFY registry. Main objectives of CAD
management are to reduce morbidity and mortality
and improve quality of life. Life style interventions,
such as smoking cessation, reduction of body weight,
increase in physical activities, control of blood pres-
sure, cholesterol plasma levels and diabetes as well
as the use of selective medications reduce the risk
of cardiovascular events and improve survival [14,
15]. The aims of pharmacological management of
stable CAD patients are to reduce angina and pre-
vent cardiovascular events [17] and three classes of
medication are shown to be essential in the treat-
ment of CAD: lipid-lowering agents, antihypertensive
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Table 3 (Continued)
Parameter 1st year 2nd year 3rd year 4th year 5th year
Smoking status N (%)
Current 5 (14.3) 2 (8.0) 1 (7.1) 2 (12.5) 1 (14.3)
Former 14 (40.0) 13 (52.0) 6 (42.9) 5 (31.2) 3 (42.9)
Never 16 (45.7) 10 (40.0) 7 (50.0) 9 (56.2) 3 (42.9)
Raised blood pressure (%)c 9 (25.7) 8 (33.3) 7 (50.0) 8 (53.3) 3 (50.0)
Raised LDL cholesterol 1 (%)d 14 (50.0) 6 (30.0) 3 (25.0) 3 (25.0) 2 (50.0)
Raised LDL cholesterol 2 (%)e 25 (89.3) 16 (80.0) 9 (75.0) 8 (66.7) 4 (100.0)
Lowered HDL cholesterol (%)f 5 (16.1) 5 (23.8) 3 (25.0) 4 (28.6) 1 (25.0)
Raised HbA1c (%)g 3 (30.0) 2 (25.0) 2 (66.7) 0 (0.0) 0 (0.0)
Started smoking (%)h 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (14.3)
BMI Body mass index, bpm beats per minute, CAD coronary artery disease, DBP diastolic blood pressure, HbA1c glycated hemoglobin, HDL high-density
lipoprotein, HR heart rate, LDL low-density lipoprotein, N number of patients, SBP systolic blood pressure, SD standard deviation
aDefined as BMI ≥ 25–29.99 kg/m2
bDefined as BMI ≥ 30 kg/m2
cDefined as systolic blood pressure ≥140mmHg and diastolic blood pressure ≥90mmHg
dDefined as LDL cholesterol plasma level ≥1 g/l or 2.6 mmol/l
eDefined as LDL cholesterol plasma level ≥0.7 g/l or 1.8 mmol/l
fDefined as HDL cholesterol plasma level ≤40mg/dl or 1.0 mmol/l
gin diabetic patients, defined as HbA1c level ≥7.0%
hfor former/never smokers at baseline
imean values as well as percentages are of the data available
Table 4 Treatment targets thatweremet5yearsafterstudy
inclusion inAustrianpatientswith stableCAD (N, [%])h
Variable Patients with stable CAD (N = 305)
Normalized blood pressurea 134/229 (58.5)
Lowered LDL cholesterol 1b 138/196 (70.4)
Lowered LDL cholesterol 2c 48/196 (24.5)
Lowered HbA1c 1d 33/77 (42.9)
Lowered HbA1c 2e 20/77 (26.0)
HR ≤ 60 bpmf 3/7 (42.9)
Smoking cessationg 16/38 (42.1)
bpm beats per minute, HbA1c glycated hemoglobin, HR heart rate, LDL low-
density lipoprotein, N number of patients
ain treated hypertensive patients, defined as systolic blood pressure
<140mmHg, diastolic blood pressure <90mmHg
bin patients with dyslipidaemia at baseline, defined as LDL cholesterol
plasma level <1.0 g/l or 2.6 mmol/l
cin patients with dyslipidaemia at baseline, defined as LDL cholesterol
plasma level <0.7 g/l or 1.8 mmol/l
din diabetic patients, defined as HbAc1 level <7.0%
ein diabetic patients, defined as HbAc1 level <6.5%
fin patients with anginal symptoms
gfor current smokers at baseline
hpercentages are of the data available
agents and antiplatelet agents [18]. Risk factors found
in Austrian outpatients with stable CAD were smok-
ing, overweight, hypertension, raised LDL cholesterol
plasma levels, elevated heart rate and a low level of
physical activity [16, 18]. Anginal symptoms were
more common in women than in men, which is con-
sistent with the data of the whole CLARIFY population
as well as the Euro Heart Survey [16, 20, 21]. It was
shown that women present with angina twice as often
as men [17]. Moreover, angina is the most frequent
manifestation of CAD in women [22]. Interestingly,
Austrian patients with angina were older than patients
without angina, which contrasts with the results of
the analysis of the international CLARIFY population
where patients with angina were slightly younger than
patients without angina. This could be the result of
the small sample size of Austrian patients with angina
compared to the patients with anginal symptoms in
the total CLARIFY registry [6]. During the 5 years of
observation there were life style improvements but
recommended goals were not achieved by the ma-
jority of patients. It is known that smoking cessation
has a positive effect on the prognosis of coronary
disease [14, 23–25] and may be the most effective of
all preventive measures. Smoking cessation is associ-
ated with a 36% reduction of mortality after MI [14],
13.2% of patients were current smokers at baseline,
after 5 years 42.1% of these patients had stopped
smoking. Another strong risk factor for cardiovas-
cular complications is diabetes mellitus [14, 19, 26].
In the present study, diabetes had been previously
diagnosed in 28.5% of all Austrian patients with CAD
and in 41.3% of patients with angina. Current guide-
lines recommend disease management with HbAc1
below 7.0% [17]. While most diabetic patients had an
HbAc1 level below 7.0% at baseline, the proportion
of patients with HbAc1 > 7.0% remained constant
during the observation period with less than half of
those patients achieving treatment goals at 5 years.
Overweight and obesity are risk factors for an increase
in all-cause mortality in general and cardiovascular
mortality in particular, because both have an adverse
effect on blood pressure, dyslipidemia and glucose
metabolism [14, 17, 23]. In the present analyses,
overweight was present in approximately three quar-
ters of patients over the whole observation period
and the presence of obesity only slightly decreased
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Table 5 Clinical events
inAustrianpatients andall
CLARIFYpatientsawith
stableCAD (N, [%])c
Event Austrian patients with stable
CAD (N = 424)
CLARIFY patients with stable
CAD (N = 31954)
All cause death 25 (5.9) 2519 (7.9)
Cardiovascular death 15 (3.5) 1604 (5.0)
Non-cardiovascular death 10 (2.4) 915 (2.9)
MI (fatal or non-fatal) 14 (3.3) 1092 (3.4)
Stroke (fatal or non-fatal) 8 (1.9) 678 (2.1)
Cardiovascular death or non-fatal MI 24 (5.7) 2329 (7.3)
Cardiovascular death, non-fatal MI or non-fatal stroke 30 (7.1) 2777 (8.7)
Non-fatal MI 9 (2.1) 786 (2.5)
Non-fatal stroke 6 (1.4) 525 (1.6)
Unstable angina 34 (8.0) 3405 (10.7)
Major bleeding 9 (2.1) 437 (1.4)
Coronary angiography 67 (15.8) 4562 (14.3)
PCI 34 (8.0) 2106 (6.6)
CABG 6 (1.4) 429 (1.3)
Revascularization (PCI or CABG) 39 (9.2) 2487 (7.8)
TIA 5 (1.2) 823 (2.6)
Hospitalization for CHF 15 (3.5) 1632 (5.1)
Cardiovascular death, non-fatal MI, non-fatal stroke or
revascularization
30 (7.1) 2777 (8.7)
MI (fatal or non-fatal) or revascularization 42 (9.9) 3068 (9.6)
MI (fatal or non-fatal) or revascularization or unstable
angina
56 (13.2) 5097 (16.0)
Cardiovascular hospitalization 124 (29.2) 9713 (30.4)
CABG coronary artery bypass graft, CHF congestive heart failure, MI myocardial infarction, N number of patients,
PCI percutaneous coronary intervention, TIA transient ischemic attack
acomplete CLARIFY population excluding Austria
bpercentages are of the data available
from 23.3% at baseline to 22.6% at 5 years. Mean
body weight, BMI as well as waist circumferences did
not change. Dyslipidemia was present in the vast
majority of Austrian patients with stable CAD. It is
recommended that dyslipidemia should be managed
according to the lipid guidelines with pharmacolog-
ical aid and life style interventions. Investigations
have shown that intensive LDL cholesterol lowering
reduces the risk of cardiovascular events in patients
with CAD. Moreover, it is associated with reduction
in plaque volume [27–29]. Treatment goals of current
guidelines are LDL cholesterol plasma levels below
1.8mmol/l (<0.7 g/l) or a more than 50% reduction of
LDL cholesterol plasma levels when the target level
cannot be achieved [17]. More than 90% of Austrian
patients were treated with LLD, which is clearly more
than found in EUROASPIRE II or the Euro Heart Sur-
vey [14, 15]. Although LLDs were widely used, target
LDL cholesterol levels <1.8mmol/l were achieved by
only 24.5% of patients. Nevertheless, 70.4% of pa-
tients could lower the LDL cholesterol plasma level
below 2.6mmol/l. A meta-analysis demonstrated that
LDL cholesterol lowering by 40mg/dl (1.04mmol/l)
resulted in a 23% decrease in CAD mortality [18];
therefore, lipid control is an unmet need that may
be improved by the use of the novel proprotein con-
vertase subtilisin/kexin type 9 (PCSK9) inhibitors
alirocumab and evolocumab.
Elevated blood pressure is a major risk factor for
CAD, heart failure and cerebrovascular disease [20].
Furthermore, high blood pressure following myocar-
dial infarction is associated with an increased risk
of reinfarction, stroke and cardiovascular death [14,
30]. Almost half of the Austrian patients with stable
CAD and half of the patients with angina had elevated
blood pressure and were treated with antihyperten-
sive agents. Among these patients, 58.5% had a blood
pressure of <140/90mmHg at the end of the observa-
tion period, which is recommended as treatment goal
[17]; however, more intensive lowering of blood pres-
sure below a systolic level of 120mmHg is associated
with both a decrease of cardiovascular events but
also blood pressure-related adverse outcomes [31].
Analyses of the international CLARIFY cohort showed
that an elevated blood pressure >140/90mmHg was
associated with an increased risk of stroke but SBP
<120mmHg and DBP <70mmHg were also associ-
ated with an increased risk of cardiovascular events
[32]. Thus, there is still uncertainty about the optimal
blood pressure target; however, taking the currently
recommended treatment target of <140/90mmHg,
hypertension is not controlled in more than 40% of
Austrian patients with stable CAD despite the broad
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Table 6 Heart rate andheart rate-modulatingmedications inEuropeanapatientswith stableCADandEuropeanapatientswith
stableCADandanginaduringobservationb
Parameter Baseline 1st year 2nd year 3rd year 4th year 5th year
Patients with stable CAD (N, [%])
17,902 17,038 16,089 14,851 13,289 11,954
HR, mean (SD) palpation (bpm) 67.3 (10.5) 66.3 (9.8) 65.9 (9.7) 66.0 (9.6) 66.1 (9.5) 66.0 (9.1)
HR, mean (SD) ECG (bpm) 66.5 (11.2) 65.7 (10.4) 65.3 (10.3) 65.4 (10.2) 65.6 (10.2) 65.5 (9.8)
Medications (N, %)
Beta-blocker 14,077 (78.7) 12,900 (76.5) 11,917 (75.9) 10,910 (75.9) 9647 (76.5) 8568 (76.7)
Ivabradine 2852 (15.9) 3182 (18.9) 3289 (20.9) 3210 (22.3) 2965 (23.5) 2695 (24.1)
Verapamil or dilitiazem 914 (5.1) 807 (4.8) 728 (4.6) 603 (4.2) 472 (3.7) 407 (3.6)
Digoxin and derivates 381 (2.1) 374 (2.2) 347 (2.2) 338 (2.3) 292 (2.3) 262 (2.3)
Patients with stable CAD and angina
(N, [%]) 4873 (27.2) 3599 (21.3) 3271 (20.6) 2929 (19.9) 2613 (19.9) 2384 (20.3)
HR, mean (SD) palpation (bpm) 69.7 (10.8) 68.2 (9.5) 67.4 (9.3) 67.3 (8.9) 66.9 (8.8) 66.9 (8.3)
HR, mean (SD) ECG (bpm) 68.8 (11.6) 67.3 (10.2) 66.5 (9.9) 66.2 (9.6) 66.1 (9.6) 66.1 (8.9)
HR ≥ 70 bpm palpation (N, %) 2351 (48.2) 1495 (41.5) 1218 (37.2) 1086 (37.1) 866 (33.1) 755 (31.7)
HR ≤ 60 bpm palpation (N, %) 1102 (22.6) 860 (23.9) 827 (25.3) 745 (25.4) 696 (26.6) 570 (23.9)
Medications (N, %)
Beta-blocker 3960 (81.3) 2944 (81.8) 2652 (81.5) 2381 (82.0) 2123 (82.4) 1917 (81.9)
Ivabradine 1417 (29.1) 1142 (31.7) 1156 (35.5) 1110 (38.2) 1030 (40.0) 925 (39.5)
Verapamil or dilitiazem 251 (5.2) 156 (4.3) 135 (4.1) 107 (3.7) 76 (3.0) 81 (3.5)
Digoxin and derivates 102 (2.1) 89 (2.5) 89 (2.7) 78 (2.7) 63 (2.4) 55 (2.4)
bpm beats per minute, HR heart rate, N number of patients, SD standard deviation
aEurope = Belgium, Bulgaria, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg Netherlands, Poland,
Portugal, Romania, Slovakia, Slovenia, Spain, Switzerland, United Kingdom, Ukraine
bmean values as well as percentages are of the data available
use of antihypertensive agents. A total of 69–79% of
patients received beta-blockers as first-line antihy-
pertensive agents and 40–45% were treated with ACE
inhibitors. The ACE inhibitors are primarily used in
patients with CAD following myocardial infarction,
in diabetic patients and patients with left ventricular
dysfunction but all other patients with CAD should
also receive ACE inhibitors once beta-blocker ther-
apy has been established [18, 33]. Of the patients
28–30% were treated with AT II receptor blockers and
finally approximately 17% received calcium antago-
nists, which are mainly used if beta-blockers are not
tolerated [34]. Heart rate is a primary determinant
of myocardial ischemia [9, 10, 12]. Heart rate lower-
ing drugs have clear anti-ischemic and anti-anginal
effects in patients with CAD [35], justifying a recom-
mended target heart rate of 55–60bpm [12]. This
target was not achieved by the majority of Austrian
patients. Moreover, and in contrast to patients in the
rest of Europe, there was no reduction in mean heart
rate over 5 years in Austrian patients with stable CAD
despite use of beta-blockers in majority of patients;
therefore, there is still much room for improvement
in HR control in the management of stable CAD. In
patients with angina and elevated HR addition of
ivabradine is one option to reduce HR without an
effect on blood pressure, thus achieving further an-
tianginal and anti-ischemic efficacy. The INITIATIVE
study showed that ivabradine is a potent anti-angi-
nal agent and is as effective as atenolol in patients
with angina [36]. Other investigations such as the
ASSOCIATE study or the ADDITIONS study showed
that ivabradine also improves symptoms and quality
of life when combined with beta-blockers in patients
with stable angina. Moreover, ivabradine produced
additional anti-anginal and anti-ischemic benefits
without untoward effects on tolerability [37–40]. Ap-
proximately one quarter of European CAD patients
and almost 40% of European patients with angina
received ivabradine as part of their CAD manage-
ment. In contrast, only approximately 6% of Austrian
patients with stable CAD received this medication.
Even in the case of patients with anginal symptoms
ivabradine was only rarely used. In years 4 and 5 of
follow-up no patient with angina was treated with
ivabradine; however, patient numbers were small,
especially in years 4 and 5.
Antiplatelet therapy is an important component of
CAD management [18]. Within the antiplatelet agents
aspirin is the most important drug in the preven-
tion of arterial thrombosis. This could also be seen
in the present analysis. The benefit of the treatment
with aspirin was shown in various studies and inter-
national guidelines [17, 36]. A meta-analysis showed
that low-dose aspirin therapy (50–325mg/day) is as-
sociated with a reduction of cardiovascular events and
the risk of all-cause mortality but an important side
effect is major bleeding [41]. Overall, 2.1% of Austrian
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patients were affected by major bleeding during the
CLARIFY observation period, which corresponds to
results in previous studies [41]. Several factors such as
treatment duration, comedications or nonadherence
to therapy have been shown to be associated with as-
pirin resistance [42]. Alternative agents are thienopy-
ridine derivates such as clopidogrel, which act as an-
tagonists of the platelet adenosine diphosphate recep-
tor P2Y12. The benefit of clopidogrel compared with
aspirin was shown in patients with previous myocar-
dial infarction, stroke or peripheral vascular disease
[43]. In Austria, thienopyridines were used in approx-
imately 10% of patients. This is consistent with the
recommendations of the European Society of Cardiol-
ogy (ESC) proposing clopidogrel as second-line treat-
ment, especially for aspirin-intolerant patients with
CAD [17].
Revascularization was performed in 9.2% of pa-
tients, but most patients had a history of PCI or
CABG. In patients with acute coronary syndromes
revascularization reduces cardiovascular death and
MI compared with conservative treatment [44, 45];
however, controversy exists over the benefit of revas-
cularization in patients with chronic stable CAD com-
pared with medical management [44, 46], and large
studies are underway to settle this issue (ISCHEMIA
trial, clinicaltrials.gov, NCT01471522). Results from
the COURAGE study implicated that PCI did not re-
duce risk of death, MI and other cardiovascular events
when added to current medical treatment in patients
with stable CAD [47]. In contrast, a large meta-anal-
ysis resulted in a benefit of revascularization. The
positive effects of revascularization are clearly shown
in patients with anginal symptoms. In these cases,
PCI or CABG more effectively relieve angina, reduce
treatment with anti-anginal drugs as well as improve
physical resilience and quality of life [48]. In this
context, the ESC guidelines recommend revascular-
ization on the basis of the presence of significant
coronary artery stenosis, the severity of ischemia and
the expected benefit for prognosis [17].
The primary outcome, defined as the composite of
cardiovascular death, MI or stroke over 5 years oc-
curred in 7.1% of patients, less frequently than in the
rest of CLARIFY population (8.7%). The same could
be found for cardiovascular death, all-cause death
and hospitalization for heart failure, whereas the fre-
quency of MI (fatal or non-fatal) and stroke (fatal or
non-fatal) was very similar. The results are consistent
with clinical trials such as COURAGE or CORONOR
as well as the Euro Heart Survey which found an
estimated annual mortality rate of 1.2–2.4%, an es-
timated annual incidence of cardiovascular death
between 0.6% and 1.4% and an estimated annual in-
cidence of non-fatal MI between 0.6% and 2.7% [47,
49, 50].
The Austrian CLARIFY cohort was relatively small,
especially the patient population with anginal symp-
toms. Thus, we cannot exclude selection bias. In ad-
dition, symptoms and outcomes were based on re-
porting by the investigator, and not on standardized
questionnaires or calibrated tests. Finally, more than
25% of patients were lost to follow-up. Thus, for a bet-
ter understanding of the management and outcome of
stable CAD in Austria studies with larger numbers of
patients are needed.
Conclusion
The characteristics of Austrian outpatients with stable
CAD corresponded to those found in other developed
countries and treatments followed the recommenda-
tions of the European guidelines. Thus, patients re-
ceived LLD, aspirin, beta-blockers and ACE inhibitors;
however, recommended goals of life style interven-
tions including a heart rate less than 60bpm and gen-
eral risk factor management were not achieved by the
majority of patients. Heart rate control and life style
changes remain unmet needs of cardiovascular care
in Austria.
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